Verastem (VSTM) Other Operating Expenses (2018 - 2026)

Verastem (VSTM) posted quarterly Other Operating Expenses of $3.1 million for Q1 2026, up 5.5% quarter-over-quarter from $2.9 million in Q4 2025.

Analysis

Verastem (VSTM) Other Operating Expenses (2018 - 2026) Analysis & Trends

Verastem's Other Operating Expenses history runs 5 years deep, the most recent figure standing at $3.1 million for Q1 2026.

In Q1 2026, Other Operating Expenses changed N/A year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $8.3 million (changed N/A YoY), while the FY2025 annual figure was $5.3 million, changed N/A from the prior year.
Other Operating Expenses for Q1 2026 stood at $3.1 million, up from $2.9 million in the prior quarter.
The five-year high for Other Operating Expenses was $3.1 million in Q1 2026, with the low at $446000.0 in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.78 Bn	130.92 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.50 Bn	77.51 Bn	3.93 Bn
3	Argenx Se	63.51 Bn	58.32 Bn	1.37 Bn
4	Moderna	58.06 Bn	52.92 Bn	52.00 Mn
5	Revolution Medicines	44.04 Bn	44.04 Bn	-
6	BeOne Medicines	40.04 Bn	34.94 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.45 Bn	32.14 Bn	992.69 Mn
8	Royalty Pharma	28.41 Bn	27.57 Bn	-
9	Insmed	27.42 Bn	26.26 Bn	358.27 Mn
10	Verastem	801.43 Mn	665.08 Mn	36.32 Mn

Historic Data

Download Data